National Lipid Association Annual Summary of Clinical Lipidology 2016

被引：94
作者：
Bays, Harold E. [1 ]
Jones, Peter H. [2 ]
Orringer, Carl E. [3 ]
Brown, W. Virgil [4 ]
Jacobson, Terry A. [5 ]
机构：
[1] Louisville Metab & Atherosclerosis Res Ctr, 3288 Illinois Ave, Louisville, KY 40213 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Univ Miami, Leonard M Miller Sch Med, Miami, FL USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] Emory Univ, Dept Med, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL LIPIDOLOGY | 2016年 / 10卷 / 01期
关键词：
Clinical Lipidology; Dyslipidemia; National Lipid Association; Annual Summary; Cholesterol; Recommendations; Guidelines; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; PATIENT-CENTERED MANAGEMENT; EVALUATING ROSUVASTATIN JUPITER; CARDIOVASCULAR RISK PREDICTION; POLYCYSTIC-OVARY-SYNDROME; SUBTILISIN/KEXIN TYPE 9; C-REACTIVE PROTEIN; TASK-FORCE;
D O I：
10.1016/j.jacl.2015.08.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The National Lipid Association (NLA) Annual Summary of Clinical Lipidology is a yearly updated summary of principles important to the patient-centered evaluation, management, and care of patients with dyslipidemia. This summary is intended to be a "living document," with future annual updates based on emerging science, clinical considerations, and new NLA Position, Consensus, and Scientific Statements, thus providing an ongoing resource that applies the latest in medical science towards the clinical management of patients with dyslipidemia. Topics include the NLA Recommendations for Patient-Centered Management of Dyslipidemia, genetics, Familial Hypercholesterolemia, secondary causes of dyslipidemia, biomarkers and advanced lipid testing, nutrition, physical activity, obesity, adiposopathy, metabolic syndrome, diabetes mellitus, lipid pharmacotherapy, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia management and treatment based upon age (children, adolescents, and older individuals), dyslipidemia considerations based upon race, ethnicity and gender, dyslipidemia and human immune virus infection, dyslipidemia and immune disorders, adherence strategies and collaborative care, and lipid-altering drugs in development. Hyperlinks direct the reader to sentinel online tables, charts, and figures relevant to lipidology, access to online atherosclerotic cardiovascular disease risk calculators, worldwide lipid guidelines, recommendations, and position/scientific statements, as well as links to online audio files, websites, slide shows, applications, continuing medical education opportunities, and patient information. (C) 2016 National Lipid Association. All rights reserved.
引用
收藏
页码：S1 / S43
页数：43
相关论文
共 202 条
[1]   Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial [J].
Albert, Michelle A. ;
Glynn, Robert J. ;
Fonseca, Francisco A. H. ;
Lorenzatti, Alberto J. ;
Ferdinand, Keith C. ;
MacFadyen, Jean G. ;
Ridker, Paul M. .
AMERICAN HEART JOURNAL, 2011, 162 (01) :106-U147
[2]  
Alexander Vickie, 2012, PREVENTION CLIN CURR
[3]  
American College of Preventive Medicine (ACPM), 2011, AM COLL PREVENTIVE M
[4]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[5]  
[Anonymous], J LIPID RES
[6]   Hypercholesterolemia and coronary heart disease in the elderly: A meta-analysis [J].
Anum, EA ;
Adera, T .
ANNALS OF EPIDEMIOLOGY, 2004, 14 (09) :705-721
[7]  
Apovian CM, 2014, PHARM MANAG IN PRESS
[8]   Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study [J].
Assmann, G. ;
Schulte, H. ;
Cullen, P. ;
Seedorf, U. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (12) :925-932
[9]   Do we need to consider inflammatory markers when we treat atherosclerotic disease? [J].
Athyros, Vasilios G. ;
Kakafika, Anna I. ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
ATHEROSCLEROSIS, 2008, 200 (01) :1-12
[10]   Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review [J].
Austin, MA ;
Hutter, CM ;
Zimmern, RL ;
Humphries, SE .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (05) :407-420
12345678910